[1] McMurray, S. E. und McMurray, C. T. (2001): Huntington's disease. A sports star and a cook, Lancet (Band 358 Suppl), Seite S38.

[2] Neurodegeneration, Definition. URL: http://www.hon.ch/cgi-bin/HONselect?search

[3] Price, D. L. und Sisodia, S. S. (1998): Mutant genes in familial Alzheimer's disease and transgenic models, Annu Rev Neurosci (Band 21), Seite 479-505.

[4] Olanow, C. W. und Tatton, W. G. (1999): Etiology and pathogenesis of Parkinson's disease, Annu Rev Neurosci (Band 22), Seite 123-44.

[5] Gusella, J. F. und MacDonald, M. E. (1996): Trinucleotide instability: a repeating theme in human inherited disorders, Annu Rev Med (Band 47), Seite 201-9.

[6] Zoghbi, H. Y. und Orr, H. T. (2000): Glutamine repeats and neurodegeneration, Annu Rev Neurosci (Band 23), Seite 217-47.

[7] Harper, P. S. (1991): Huntington's Disease, W. B. Saunders, London.

[8] Telenius, H.; Kremer, H. P.; Theilmann, J.; Andrew, S. E.; Almqvist, E.; Anvret, M.; Greenberg, C.; Greenberg, J.; Lucotte, G.; Squitieri, F. und et al. (1993): Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent, Hum Mol Genet (Band 2), Nr. 10, Seite 1535-40.

[9] HDCRG (1993): A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group, Cell (Band 72), Nr. 6, Seite 971-83.

[10] McMurray, C. T. (2001): Huntington's disease. Expanding horizons for treatment, Lancet (Band 358 Suppl), Seite S37.

[11] Wanker, E. E. (2000): Protein aggregation and pathogenesis of Huntington's disease: mechanisms and correlations, Biol Chem (Band 381), Nr. 9-10, Seite 937-42.

[12] Sharp, A. H. und Ross, C. A. (1996): Neurobiology of Huntington's disease, Neurobiol Dis (Band 3), Nr. 1, Seite 3-15.

[13] Li, H.; Li, S. H.; Johnston, H.; Shelbourne, P. F. und Li, X. J. (2000): Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity, Nat Genet (Band 25), Nr. 4, Seite 385-9.

[14] Velier, J.; Kim, M.; Schwarz, C.; Kim, T. W.; Sapp, E.; Chase, K.; Aronin, N. und DiFiglia, M. (1998): Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways, Exp Neurol (Band 152), Nr. 1, Seite 34-40.

[15] Zuccato, C.; Ciammola, A.; Rigamonti, D.; Leavitt, B. R.; Goffredo, D.; Conti, L.; MacDonald, M. E.; Friedlander, R. M.; Silani, V.; Hayden, M. R.; Timmusk, T.; Sipione, S. und Cattaneo, E. (2001): Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease, Science (Band 293), Nr. 5529, Seite 493-8.

[16] Bates, G. P. (2001): Huntington's disease. Exploiting expression, Nature (Band 413), Nr. 6857, Seite 691, 693-4.

[17] Steffan, J. S.; Bodai, L.; Pallos, J.; Poelman, M.; McCampbell, A.; Apostol, B. L.; Kazantsev, A.; Schmidt, E.; Zhu, Y. Z.; Greenwald, M.; Kurokawa, R.; Housman, D. E.; Jackson, G. R.; Marsh, J. L. und Thompson, L. M. (2001): Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila, Nature (Band 413), Nr. 6857, Seite 739-43.

[18] McCampbell, A.; Taye, A. A.; Whitty, L.; Penney, E.; Steffan, J. S. und Fischbeck, K. H. (2001): Histone deacetylase inhibitors reduce polyglutamine toxicity, Proc Natl Acad Sci U S A (Band 98), Nr. 26, Seite 15179-84. URL: http://www.pnas.org/cgi/content/abstract/98/26/15179

[19] Peters, P. J.; Ning, K.; Palacios, F.; Boshans, R. L.; Kazantsev, A.; Thompson, L. M.; Woodman, B.; Bates, G. P. und D'Souza-Schorey, C. (2002): Arfaptin 2 regulates the aggregation of mutant huntingtin protein, Nat Cell Biol (Band 4), Nr. 3, Seite 240-5.

[20] Gervais, F. G.; Singaraja, R.; Xanthoudakis, S.; Gutekunst, C. A.; Leavitt, B. R.; Metzler, M.; Hackam, A. S.; Tam, J.; Vaillancourt, J. P.; Houtzager, V.; Rasper, D. M.; Roy, S.; Hayden, M. R. und Nicholson, D. W. (2002): Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi, Nat Cell Biol (Band 4), Nr. 2, Seite 95-105.

[21] Mattson, M. P. (2000): Apoptosis in neurodegenerative disorders, Nat Rev Mol Cell Biol (Band 1), Nr. 2, Seite 120-9.

[22] Li, H.; Li, S. H.; Cheng, A. L.; Mangiarini, L.; Bates, G. P. und Li, X. J. (1999): Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice, Hum Mol Genet (Band 8), Nr. 7, Seite 1227-36.

[23] Turmaine, M.; Raza, A.; Mahal, A.; Mangiarini, L.; Bates, G. P. und Davies, S. W. (2000): Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease, Proc Natl Acad Sci U S A (Band 97), Nr. 14, Seite 8093-7.

[24] Earnshaw, W. C.; Martins, L. M. und Kaufmann, S. H. (1999): Mammalian caspases: structure, activation, substrates, and functions during apoptosis, Annu Rev Biochem (Band 68), Seite 383-424.

[25] Lansbury, P. T., Jr. (1997): Structural neurology: are seeds at the root of neuronal degeneration?, Neuron (Band 19), Nr. 6, Seite 1151-4.

[26] Lin, X.; Cummings, C. J. und Zoghbi, H. Y. (1999): Expanding our understanding of polyglutamine diseases through mouse models, Neuron (Band 24), Nr. 3, Seite 499-502.

[27] Dyer, R. B. und McMurray, C. T. (2001): Mutant protein in Huntington disease is resistant to proteolysis in affected brain, Nat Genet (Band 29), Nr. 3, Seite 270-8.

[28] Kim, Y. J.; Yi, Y.; Sapp, E.; Wang, Y.; Cuiffo, B.; Kegel, K. B.; Qin, Z. H.; Aronin, N. und DiFiglia, M. (2001): Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis, Proc Natl Acad Sci U S A (Band 98), Nr. 22, Seite 12784-9. URL: http://www.pnas.org/cgi/content/abstract/98/22/12784

[29] Wellington, C. L.; Singaraja, R.; Ellerby, L.; Savill, J.; Roy, S.; Leavitt, B.; Cattaneo, E.; Hackam, A.; Sharp, A.; Thornberry, N.; Nicholson, D. W.; Bredesen, D. E. und Hayden, M. R. (2000): Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells, J Biol Chem (Band 275), Nr. 26, Seite 19831-8.

[30] Wellington, C. L.; Ellerby, L. M.; Hackam, A. S.; Margolis, R. L.; Trifiro, M. A.; Singaraja, R.; McCutcheon, K.; Salvesen, G. S.; Propp, S. S.; Bromm, M.; Rowland, K. J.; Zhang, T.; Rasper, D.; Roy, S.; Thornberry, N.; Pinsky, L.; Kakizuka, A.; Ross, C. A.; Nicholson, D. W.; Bredesen, D. E. und Hayden, M. R. (1998): Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract, J Biol Chem (Band 273), Nr. 15, Seite 9158-67.

[31] DiFiglia, M.; Sapp, E.; Chase, K. O.; Davies, S. W.; Bates, G. P.; Vonsattel, J. P. und Aronin, N. (1997): Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain, Science (Band 277), Nr. 5334, Seite 1990-3.

[32] Gutekunst, C. A.; Li, S. H.; Yi, H.; Mulroy, J. S.; Kuemmerle, S.; Jones, R.; Rye, D.; Ferrante, R. J.; Hersch, S. M. und Li, X. J. (1999): Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology, J Neurosci (Band 19), Nr. 7, Seite 2522-34.

[33] Davies, S. W.; Turmaine, M.; Cozens, B. A.; DiFiglia, M.; Sharp, A. H.; Ross, C. A.; Scherzinger, E.; Wanker, E. E.; Mangiarini, L. und Bates, G. P. (1997): Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation, Cell (Band 90), Nr. 3, Seite 537-48.

[34] Schilling, G.; Becher, M. W.; Sharp, A. H.; Jinnah, H. A.; Duan, K.; Kotzuk, J. A.; Slunt, H. H.; Ratovitski, T.; Cooper, J. K.; Jenkins, N. A.; Copeland, N. G.; Price, D. L.; Ross, C. A. und Borchelt, D. R. (1999): Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin, Hum Mol Genet (Band 8), Nr. 3, Seite 397-407.

[35] Mende-Mueller, L. M.; Toneff, T.; Hwang, S. R.; Chesselet, M. F. und Hook, V. Y. (2001): Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum, J Neurosci (Band 21), Nr. 6, Seite 1830-7. URL: http://www.jneurosci.org/cgi/content/abstract/21/6/1830

[36] Saudou, F.; Finkbeiner, S.; Devys, D. und Greenberg, M. E. (1998): Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions, Cell (Band 95), Nr. 1, Seite 55-66.

[37] Kim, M.; Lee, H. S.; LaForet, G.; McIntyre, C.; Martin, E. J.; Chang, P.; Kim, T. W.; Williams, M.; Reddy, P. H.; Tagle, D.; Boyce, F. M.; Won, L.; Heller, A.; Aronin, N. und DiFiglia, M. (1999): Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition, J Neurosci (Band 19), Nr. 3, Seite 964-73. URL: http://www.jneurosci.org/cgi/content/full/19/3/964

[38] Sanchez, I.; Xu, C. J.; Juo, P.; Kakizaka, A.; Blenis, J. und Yuan, J. (1999): Caspase-8 is required for cell death induced by expanded polyglutamine repeats

[see comments], Neuron (Band 22), Nr. 3, Seite 623-33.

[39] Huang, E. J. und Reichardt, L. F. (2001): Neurotrophins: roles in neuronal development and function, Annu Rev Neurosci (Band 24), Seite 677-736. URL: http://neuro.annualreviews.org/cgi/content/abstract/24/1/677

[40] Cha, J. H.; Kosinski, C. M.; Kerner, J. A.; Alsdorf, S. A.; Mangiarini, L.; Davies, S. W.; Penney, J. B.; Bates, G. P. und Young, A. B. (1998): Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene, Proc Natl Acad Sci U S A (Band 95), Nr. 11, Seite 6480-5.

[41] Mangiarini, L.; Sathasivam, K.; Seller, M.; Cozens, B.; Harper, A.; Hetherington, C.; Lawton, M.; Trottier, Y.; Lehrach, H.; Davies, S. W. und Bates, G. P. (1996): Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice, Cell (Band 87), Nr. 3, Seite 493-506.

[42] Perez-Severiano, F.; Rios, C. und Segovia, J. (2000): Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington's disease, Brain Res (Band 862), Nr. 1-2, Seite 234-7.

[43] Roy, S. und Nicholson, D. W. (2000): Cross-talk in cell death signaling, J Exp Med (Band 192), Nr. 8, Seite F21-5. URL: http://www.jem.org/cgi/content/full/192/8/F21

[44] Chen, M.; Ona, V. O.; Li, M.; Ferrante, R. J.; Fink, K. B.; Zhu, S.; Bian, J.; Guo, L.; Farrell, L. A.; Hersch, S. M.; Hobbs, W.; Vonsattel, J. P.; Cha, J. H. und Friedlander, R. M. (2000): Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease, Nat Med (Band 6), Nr. 7, Seite 797-801.

[45] Ferri, K. F. und Kroemer, G. (2001): Organelle-specific initiation of cell death pathways, Nat Cell Biol (Band 3), Nr. 11, Seite E255-63.

[46] Kroemer, G.; Dallaporta, B. und Resche-Rigon, M. (1998): The mitochondrial death/life regulator in apoptosis and necrosis, Annu Rev Physiol (Band 60), Seite 619-42.

[47] Portera-Cailliau, C.; Hedreen, J. C.; Price, D. L. und Koliatsos, V. E. (1995): Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models, J Neurosci (Band 15), Nr. 5 Pt 2, Seite 3775-87.

[48] Dragunow, M.; Faull, R. L.; Lawlor, P.; Beilharz, E. J.; Singleton, K.; Walker, E. B. und Mee, E. (1995): In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes, Neuroreport (Band 6), Nr. 7, Seite 1053-7.

[49] Mattson, M. P. und Camandola, S. (2001): NF-kappaB in neuronal plasticity and neurodegenerative disorders, J Clin Invest (Band 107), Nr. 3, Seite 247-54. URL: http://www.jci.org/cgi/content/full/107/3/247

[50] Sisodia, S. S. (1998): Nuclear inclusions in glutamine repeat disorders: are they pernicious, coincidental, or beneficial?, Cell (Band 95), Nr. 1, Seite 1-4.

[51] Klement, I. A.; Skinner, P. J.; Kaytor, M. D.; Yi, H.; Hersch, S. M.; Clark, H. B.; Zoghbi, H. Y. und Orr, H. T. (1998): Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice, Cell (Band 95), Nr. 1, Seite 41-53.

[52] Kuemmerle, S.; Gutekunst, C. A.; Klein, A. M.; Li, X. J.; Li, S. H.; Beal, M. F.; Hersch, S. M. und Ferrante, R. J. (1999): Huntington aggregates may not predict neuronal death in Huntington's disease, Ann Neurol (Band 46), Nr. 6, Seite 842-9.

[53] Ona, V. O.; Li, M.; Vonsattel, J. P.; Andrews, L. J.; Khan, S. Q.; Chung, W. M.; Frey, A. S.; Menon, A. S.; Li, X. J.; Stieg, P. E.; Yuan, J.; Penney, J. B.; Young, A. B.; Cha, J. H. und Friedlander, R. M. (1999): Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease, Nature (Band 399), Nr. 6733, Seite 263-7.

[54] Vonsattel, J. P.; Myers, R. H.; Stevens, T. J.; Ferrante, R. J.; Bird, E. D. und Richardson, E. P. (1985): Neuropathological classification of Huntington's disease, J Neuropathol Exp Neurol (Band 44), Nr. 6, Seite 559-77.

[55] Trottier, Y.; Lutz, Y.; Stevanin, G.; Imbert, G.; Devys, D.; Cancel, G.; Saudou, F.; Weber, C.; David, G.; Tora, L. und et al. (1995): Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias, Nature (Band 378), Nr. 6555, Seite 403-6.

[56] Chorea, Definition. URL: http://neuroscript.com/

[57] Reddy, P. H.; Williams, M.; Charles, V.; Garrett, L.; Pike-Buchanan, L.; Whetsell, W. O.; Miller, G. und Tagle, D. A. (1998): Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA, Nat Genet (Band 20), Nr. 2, Seite 198-202.

[58] Wheeler, V. C.; White, J. K.; Gutekunst, C. A.; Vrbanac, V.; Weaver, M.; Li, X. J.; Li, S. H.; Yi, H.; Vonsattel, J. P.; Gusella, J. F.; Hersch, S.; Auerbach, W.; Joyner, A. L. und MacDonald, M. E. (2000): Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice, Hum Mol Genet (Band 9), Nr. 4, Seite 503-13.

[59] Wheeler, V. C.; Gutekunst, C. A.; Vrbanac, V.; Lebel, L. A.; Schilling, G.; Hersch, S.; Friedlander, R. M.; Gusella, J. F.; Vonsattel, J. P.; Borchelt, D. R. und MacDonald, M. E. (2002): Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice, Hum Mol Genet (Band 11), Nr. 6, Seite 633-640. URL: http://hmg.oupjournals.org/cgi/content/abstract/11/6/633

[60] Carter, R. J.; Lione, L. A.; Humby, T.; Mangiarini, L.; Mahal, A.; Bates, G. P.; Dunnett, S. B. und Morton, A. J. (1999): Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation, J Neurosci (Band 19), Nr. 8, Seite 3248-57.

[61] Lione, L. A.; Carter, R. J.; Hunt, M. J.; Bates, G. P.; Morton, A. J. und Dunnett, S. B. (1999): Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation, J Neurosci (Band 19), Nr. 23, Seite 10428-37.

[62] Murphy, K. P.; Carter, R. J.; Lione, L. A.; Mangiarini, L.; Mahal, A.; Bates, G. P.; Dunnett, S. B. und Morton, A. J. (2000): Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation, J Neurosci (Band 20), Nr. 13, Seite 5115-23.

[63] Sathasivam, K.; Hobbs, C.; Turmaine, M.; Mangiarini, L.; Mahal, A.; Bertaux, F.; Wanker, E. E.; Doherty, P.; Davies, S. W. und Bates, G. P. (1999): Formation of polyglutamine inclusions in non-CNS tissue, Hum Mol Genet (Band 8), Nr. 5, Seite 813-22.

[64] Reynolds, G. P.; Dalton, C. F.; Tillery, C. L.; Mangiarini, L.; Davies, S. W. und Bates, G. P. (1999): Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation, J Neurochem (Band 72), Nr. 4, Seite 1773-6.

[65] Mangiarini, L.; Sathasivam, K.; Mahal, A.; Mott, R.; Seller, M. und Bates, G. P. (1997): Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation, Nat Genet (Band 15), Nr. 2, Seite 197-200.

[66] Fain, J. N.; Del Mar, N. A.; Meade, C. A.; Reiner, A. und Goldowitz, D. (2001): Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington's disease mutation, Hum Mol Genet (Band 10), Nr. 2, Seite 145-52. URL: http://hmg.oupjournals.org/cgi/content/abstract/10/2/145

[67] Davies, S. W.; Turmaine, M.; Cozens, B. A.; Raza, A. S.; Mahal, A.; Mangiarini, L. und Bates, G. P. (1999): From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease, Philos Trans R Soc Lond B Biol Sci (Band 354), Nr. 1386, Seite 981-9.

[68] Denovan-Wright, E. M. und Robertson, H. A. (2000): Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice, Neuroscience (Band 98), Nr. 4, Seite 705-13.

[69] Bibb, J. A.; Yan, Z.; Svenningsson, P.; Snyder, G. L.; Pieribone, V. A.; Horiuchi, A.; Nairn, A. C.; Messer, A. und Greengard, P. (2000): Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice, Proc Natl Acad Sci U S A (Band 97), Nr. 12, Seite 6809-14.

[70] Glass, M.; Dragunow, M. und Faull, R. L. (2000): The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease, Neuroscience (Band 97), Nr. 3, Seite 505-19.

[71] Augood, S. J.; Faull, R. L.; Love, D. R. und Emson, P. C. (1996): Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study, Neuroscience (Band 72), Nr. 4, Seite 1023-36.

[72] Weeks, R. A.; Piccini, P.; Harding, A. E. und Brooks, D. J. (1996): Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease, Ann Neurol (Band 40), Nr. 1, Seite 49-54.

[73] Luthi-Carter, R.; Strand, A.; Peters, N. L.; Solano, S. M.; Hollingsworth, Z. R.; Menon, A. S.; Frey, A. S.; Spektor, B. S.; Penney, E. B.; Schilling, G.; Ross, C. A.; Borchelt, D. R.; Tapscott, S. J.; Young, A. B.; Cha, J. H. und Olson, J. M. (2000): Decreased expression of striatal signaling genes in a mouse model of Huntington's disease, Hum Mol Genet (Band 9), Nr. 9, Seite 1259-71.

[74] Greengard, P.; Allen, P. B. und Nairn, A. C. (1999): Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade, Neuron (Band 23), Nr. 3, Seite 435-47.

[75] Perez, M. K.; Paulson, H. L.; Pendse, S. J.; Saionz, S. J.; Bonini, N. M. und Pittman, R. N. (1998): Recruitment and the role of nuclear localization in polyglutamine- mediated aggregation, J Cell Biol (Band 143), Nr. 6, Seite 1457-70.

[76] Kazantsev, A.; Preisinger, E.; Dranovsky, A.; Goldgaber, D. und Housman, D. (1999): Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells, Proc Natl Acad Sci U S A (Band 96), Nr. 20, Seite 11404-9. URL: http://www.pnas.org/cgi/content/abstract/96/20/11404

[77] Head, M. W. und Goldman, J. E. (2000): Small heat shock proteins, the cytoskeleton, and inclusion body formation, Neuropathol Appl Neurobiol (Band 26), Nr. 4, Seite 304-12.

[78] Cummings, C. J.; Mancini, M. A.; Antalffy, B.; DeFranco, D. B.; Orr, H. T. und Zoghbi, H. Y. (1998): Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1, Nat Genet (Band 19), Nr. 2, Seite 148-54.

[79] Steffan, J. S.; Kazantsev, A.; Spasic-Boskovic, O.; Greenwald, M.; Zhu, Y. Z.; Gohler, H.; Wanker, E. E.; Bates, G. P.; Housman, D. E. und Thompson, L. M. (2000): The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription, Proc Natl Acad Sci U S A (Band 97), Nr. 12, Seite 6763-8.

[80] Nucifora, F. C., Jr.; Sasaki, M.; Peters, M. F.; Huang, H.; Cooper, J. K.; Yamada, M.; Takahashi, H.; Tsuji, S.; Troncoso, J.; Dawson, V. L.; Dawson, T. M. und Ross, C. A. (2001): Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity, Science (Band 291), Nr. 5512, Seite 2423-8. URL: http://www.sciencemag.org/cgi/content/abstract/291/5512/2423

[81] Jana, N. R.; Tanaka, M.; Wang, Gh und Nukina, N. (2000): Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity, Hum Mol Genet (Band 9), Nr. 13, Seite 2009-18. URL: http://hmg.oupjournals.org/cgi/content/abstract/9/13/2009

[82] Koyama, Y. und Goldman, J. E. (1999): Formation of GFAP cytoplasmic inclusions in astrocytes and their disaggregation by alphaB-crystallin, Am J Pathol (Band 154), Nr. 5, Seite 1563-72.

[83] Muchowski, P. J.; Schaffar, G.; Sittler, A.; Wanker, E. E.; Hayer-Hartl, M. K. und Hartl, F. U. (2000): Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils, Proc Natl Acad Sci U S A (Band 97), Nr. 14, Seite 7841-6.

[84] Head, M. W.; Corbin, E. und Goldman, J. E. (1993): Overexpression and abnormal modification of the stress proteins alpha B-crystallin and HSP27 in Alexander disease, Am J Pathol (Band 143), Nr. 6, Seite 1743-53.

[85] Iwaki, T.; Wisniewski, T.; Iwaki, A.; Corbin, E.; Tomokane, N.; Tateishi, J. und Goldman, J. E. (1992): Accumulation of alpha B-crystallin in central nervous system glia and neurons in pathologic conditions, Am J Pathol (Band 140), Nr. 2, Seite 345-56.

[86] Renkawek, K.; Voorter, C. E.; Bosman, G. J.; van Workum, F. P. und de Jong, W. W. (1994): Expression of alpha B-crystallin in Alzheimer's disease, Acta Neuropathol (Berl) (Band 87), Nr. 2, Seite 155-60.

[87] Swinbanks, D. (1995): Government backs proteome proposal, Nature (Band 378), Nr. 6558, Seite 653.

[88] Klose, J. (1999): Fractionated extraction of total tissue proteins from mouse and human for 2-D electrophoresis, Methods Mol Biol (Band 112), Seite 67-85.

[89] Klose, J. (1999): Large-gel 2-D electrophoresis, Methods Mol Biol (Band 112), Seite 147-72.

[90] Klose, J. und Kobalz, U. (1995): Two-dimensional electrophoresis of proteins: an updated protocol and implications for a functional analysis of the genome, Electrophoresis (Band 16), Nr. 6, Seite 1034-59.

[91] Heukeshoven, J. und Dernick, R. (1985): Simplified Method For Silver Staining of Proteins in Polyacrylamide Gels and the mechanism of silver staining, Electrophoresis (Band 6), Nr. 3, Seite 103-112.

[92] Jungblut, P. R. und Seifert, R. (1990): Analysis by high-resolution two-dimensional electrophoresis of differentiation-dependent alterations in cytosolic protein pattern of HL-60 leukemic cells, J Biochem Biophys Methods (Band 21), Nr. 1, Seite 47-58.

[93] Doherty, N. S.; Littman, B. H.; Reilly, K.; Swindell, A. C.; Buss, J. M. und Anderson, N. L. (1998): Analysis of changes in acute-phase plasma proteins in an acute inflammatory response and in rheumatoid arthritis using two-dimensional gel electrophoresis, Electrophoresis (Band 19), Nr. 2, Seite 355-63.

[94] Scheler, C.; Lamer, S.; Pan, Z.; Li, X. P.; Salnikow, J. und Jungblut, P. (1998): Peptide mass fingerprint sequence coverage from differently stained proteins on two-dimensional electrophoresis patterns by matrix assisted laser desorption/ionization-mass spectrometry (MALDI-MS), Electrophoresis (Band 19), Nr. 6, Seite 918-27.

[95] Klose, J.; Nock, C.; Herrmann, M.; Stuhler, K.; Marcus, K.; Bluggel, M.; Krause, E.; Schalkwyk, L. C.; Rastan, S.; Brown, S. D.; Bussow, K.; Himmelbauer, H. und Lehrach, H. (2002): Genetic analysis of the mouse brain proteome, Nat Genet (Band 30), Nr. 4, Seite 385-93.

[96] Gevaert, K.; Verschelde, J. L.; Puype, M.; Van Damme, J.; Goethals, M.; De Boeck, S. und Vandekerckhove, J. (1996): Structural analysis and identification of gel-purified proteins, available in the femtomole range, using a novel computer program for peptide sequence assignment, by matrix-assisted laser desorption ionization-reflectron time-of-flight-mass spectrometry, Electrophoresis (Band 17), Nr. 5, Seite 918-24.

[97] Immler, D.; Gremm, D.; Kirsch, D.; Spengler, B.; Presek, P. und Meyer, H. E. (1998): Identification of phosphorylated proteins from thrombin-activated human platelets isolated by two-dimensional gel electrophoresis by electrospray ionization-tandem mass spectrometry (ESI-MS/MS) and liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS), Electrophoresis (Band 19), Nr. 6, Seite 1015-23.

[98] Zhang, W. und Chait, B. T. (2000): ProFound: an expert system for protein identification using mass spectrometric peptide mapping information, Anal Chem (Band 72), Nr. 11, Seite 2482-9.

[99] Eng, J.; McCormack, A. L. und Yates III, J. R. (1994): An Approach to Correlate Tandem Mass Spectral Data of Peptides with Amino Acid Sequences in a Protein Database, Journal of the American Society for Mass Spectrometry (Band 5), Seite 976-989.

[100] Yates, J. R.; Eng, J. K.; McCormack, A. L. und Schieltz, D. (1995): Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database, Anal Chem (Band 67), Nr. 8, Seite 1426-36.

[101] Yates, J. R.; Eng, J. K. und McCormack, A. L. (1995): Mining genomes: correlating tandem mass spectra of modified and unmodified peptides to sequences in nucleotide databases, Anal Chem (Band 67), Nr. 18, Seite 3202-10.

[102] Jungblut, P. R.; Zimny-Arndt, U.; Zeindl-Eberhart, E.; Stulik, J.; Koupilova, K.; Pleissner, K. P.; Otto, A.; Muller, E. C.; Sokolowska-Kohler, W.; Grabher, G. und Stoffler, G. (1999): Proteomics in human disease: cancer, heart and infectious diseases, Electrophoresis (Band 20), Nr. 10, Seite 2100-10.

[103] Bestimmung, pI. URL: http://www.expasy.ch/tools/peptide-mass.html

[104] Clissold, P. M. und Bishop, J. O. (1982): Variation in mouse major urinary protein (MUP) genes and the MUP gene products within and between inbred lines, Gene (Band 18), Nr. 3, Seite 211-20.

[105] Flower, D. R.; North, A. C. und Sansom, C. E. (2000): The lipocalin protein family: structural and sequence overview, Biochim Biophys Acta (Band 1482), Nr. 1-2, Seite 9-24.

[106] Baumann, H. und Gauldie, J. (1994): The acute phase response, Immunol Today (Band 15), Nr. 2, Seite 74-80.

[107] Gollin, P. A.; Kalaria, R. N.; Eikelenboom, P.; Rozemuller, A. und Perry, G. (1992): Alpha 1-antitrypsin and alpha 1-antichymotrypsin are in the lesions of Alzheimer's disease, Neuroreport (Band 3), Nr. 2, Seite 201-3.

[108] Takahara, H. und Sinohara, H. (1982): Mouse plasma trypsin inhibitors. Isolation and characterization of alpha-1-antitrypsin and contrapsin, a novel trypsin inhibitor, J Biol Chem (Band 257), Nr. 5, Seite 2438-46.

[109] Hill, R. E.; Shaw, P. H.; Boyd, P. A.; Baumann, H. und Hastie, N. D. (1984): Plasma protease inhibitors in mouse and man: divergence within the reactive centre regions, Nature (Band 311), Nr. 5982, Seite 175-7.

[110] Vonsattel, J. P. und DiFiglia, M. (1998): Huntington disease, J Neuropathol Exp Neurol (Band 57), Nr. 5, Seite 369-84.

[111] Finotti, P. und Pagetta, A. (1997): Albumin contamination of a purified human alpha 1-antitrypsin preparation does not affect either structural conformation or the electrophoretic mobility of the inhibitor, Clin Chim Acta (Band 264), Nr. 2, Seite 133-48.

[112] Finotti, P. und de Laureto, P. P. (1997): Differential effects of heparin and glucose on structural conformation of human alpha1 antitrypsin: evidence for a heparin-induced cleaved form of the inhibitor, Arch Biochem Biophys (Band 347), Nr. 1, Seite 19-29.

[113] Borriello, F. und Krauter, K. S. (1991): Multiple murine alpha 1-protease inhibitor genes show unusual evolutionary divergence, Proc Natl Acad Sci U S A (Band 88), Nr. 21, Seite 9417-21.

[114] Silverman, G. A.; Bird, P. I.; Carrell, R. W.; Church, F. C.; Coughlin, P. B.; Gettins, P. G.; Irving, J. A.; Lomas, D. A.; Luke, C. J.; Moyer, R. W.; Pemberton, P. A.; Remold-O'Donnell, E.; Salvesen, G. S.; Travis, J. und Whisstock, J. C. (2001): The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature, J Biol Chem (Band 276), Nr. 36, Seite 33293-6. URL: http://www.jbc.org/cgi/content/full/276/36/33293

[115] Goodwin, R. L.; Barbour, K. W. und Berger, F. G. (1997): Expression of the alpha 1-proteinase inhibitor gene family during evolution of the genus Mus, Mol Biol Evol (Band 14), Nr. 4, Seite 420-7.

[116] Schubert, D. (1997): Serpins inhibit the toxicity of amyloid peptides, Eur J Neurosci (Band 9), Nr. 4, Seite 770-7.

[117] Ikari, Y.; Mulvihill, E. und Schwartz, S. M. (2001): alpha 1-Proteinase inhibitor, alpha 1-antichymotrypsin, and alpha 2-macroglobulin are the antiapoptotic factors of vascular smooth muscle cells, J Biol Chem (Band 276), Nr. 15, Seite 11798-803.

[118] Daemen, M. A.; Heemskerk, V. H.; van't Veer, C.; Denecker, G.; Wolfs, T. G.; Vandenabeele, P. und Buurman, W. A. (2000): Functional protection by acute phase proteins alpha(1)-acid glycoprotein and alpha(1)-antitrypsin against ischemia/reperfusion injury by preventing apoptosis and inflammation, Circulation (Band 102), Nr. 12, Seite 1420-6.

[119] Keppler, D.; Lesch, R.; Reutter, W. und Decker, K. (1968): Experimental hepatitis induced by D-galactosamine, Exp Mol Pathol (Band 9), Nr. 2, Seite 279-90.

[120] Van Molle, W.; Denecker, G.; Rodriguez, I.; Brouckaert, P.; Vandenabeele, P. und Libert, C. (1999): Activation of caspases in lethal experimental hepatitis and prevention by acute phase proteins, J Immunol (Band 163), Nr. 10, Seite 5235-41.

[121] Arrell, D. K.; Neverova, I. und Van Eyk, J. E. (2001): Cardiovascular proteomics: evolution and potential, Circ Res (Band 88), Nr. 8, Seite 763-73. URL: http://www.circresaha.org/cgi/content/abstract/88/8/763

[122] Li, X. P.; Pleissner, K. P.; Scheler, C.; Regitz-Zagrosek, V.; Salnikow, J. und Jungblut, P. R. (1999): A two-dimensional electrophoresis database of rat heart proteins, Electrophoresis (Band 20), Nr. 4-5, Seite 891-7.

[123] Horwitz, J. (1992): Alpha-crystallin can function as a molecular chaperone, Proc Natl Acad Sci U S A (Band 89), Nr. 21, Seite 10449-53.

[124] Klemenz, R.; Frohli, E.; Steiger, R. H.; Schafer, R. und Aoyama, A. (1991): Alpha B-crystallin is a small heat shock protein, Proc Natl Acad Sci U S A (Band 88), Nr. 9, Seite 3652-6.

[125] Dubin, R. A.; Wawrousek, E. F. und Piatigorsky, J. (1989): Expression of the murine alpha B-crystallin gene is not restricted to the lens, Mol Cell Biol (Band 9), Nr. 3, Seite 1083-91.

[126] Bajramovic, J. J.; Bsibsi, M.; Geutskens, S. B.; Hassankhan, R.; Verhulst, K. C.; Stege, G. J.; de Groot, C. J. und van Noort, J. M. (2000): Differential expression of stress proteins in human adult astrocytes in response to cytokines, J Neuroimmunol (Band 106), Nr. 1-2, Seite 14-22.

[127] Aoyama, A.; Steiger, R. H.; Frohli, E.; Schafer, R.; von Deimling, A.; Wiestler, O. D. und Klemenz, R. (1993): Expression of alpha B-crystallin in human brain tumors, Int J Cancer (Band 55), Nr. 5, Seite 760-4.

[128] Zhou, H.; Li, S. H. und Li, X. J. (2001): Chaperone suppression of cellular toxicity of huntingtin is independent of polyglutamine aggregation, J Biol Chem (Band 276), Nr. 51, Seite 48417-424.

[129] Cavaggioni, A. und Mucignat-Caretta, C. (2000): Major urinary proteins, alpha(2U)-globulins and aphrodisin, Biochim Biophys Acta (Band 1482), Nr. 1-2, Seite 218-28.

[130] Wicks, L. F. (1941), Proc. Soc. Exp. Biol. Med. (Band 48), Seite 395-400.

[131] Bacchini, A.; Gaetani, E. und Cavaggioni, A. (1992): Pheromone binding proteins of the mouse, Mus musculus, Experientia (Band 48), Nr. 4, Seite 419-21.

[132] Brennan, P. A. (2001): The vomeronasal system, Cell Mol Life Sci (Band 58), Nr. 4, Seite 546-55.

[133] Hurst, J. L.; Payne, C. E.; Nevison, C. M.; Marie, A. D.; Humphries, R. E.; Robertson, D. H.; Cavaggioni, A. und Beynon, R. J. (2001): Individual recognition in mice mediated by major urinary proteins, Nature (Band 414), Nr. 6864, Seite 631-634.

[134] Marchlewska-Koj, A.; Cavaggioni, A.; Mucignat-Caretta, C. und Olejniczak, P. (2000): Stimulation of estrus in female mice by male urinary proteins, Journal of Chemical Ecology (Band 26), Nr. 10, Seite 2355-2366.

[135] Sironi, L.; Tremoli, E.; Miller, I.; Guerrini, U.; Calvio, A. M.; Eberini, I.; Gemeiner, M.; Asdente, M.; Paoletti, R. und Gianazza, E. (2001): Acute-phase proteins before cerebral ischemia in stroke-prone rats: identification by proteomics, Stroke (Band 32), Nr. 3, Seite 753-60.

[136] Kalchman, M. A.; Koide, H. B.; McCutcheon, K.; Graham, R. K.; Nichol, K.; Nishiyama, K.; Kazemi-Esfarjani, P.; Lynn, F. C.; Wellington, C.; Metzler, M.; Goldberg, Y. P.; Kanazawa, I.; Gietz, R. D. und Hayden, M. R. (1997): HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain, Nat Genet (Band 16), Nr. 1, Seite 44-53.